H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Ligand (LGND) to $289 from $243 and keeps a Buy rating on the shares. The firm cites the company’s acquisition of Xoma for the target boost. Beyond the “immediately accretive” approved assets of Xoma, H.C. Wainwright sees “strong potential upside from multiple late stage assets as well as a very deep developmental pipeline,” the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand price target raised to $252 from $235 at RBC Capital
- Analyst Reiterates Buy on Ligand, Lifts Price Target to $260 on Royalty Portfolio Expansion from XOMA Acquisition
- Ligand price target raised to $255 from $230 at Stifel
- Ligand price target raised to $260 from $250 at BofA
- Ligand Pharma to Acquire XOMA, Expands Royalty Portfolio